PLX R18

Drug Profile

PLX R18

Alternative Names: PLX-R-18; PLX-RAD

Latest Information Update: 31 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hadassah Medical School; Pluristem Therapeutics
  • Developer Case Western Reserve University; Fukushima Medical University; Hadassah Medical School; National Institute of Allergy and Infectious Diseases; Pluristem Therapeutics; United States Department of Defense
  • Class Stem cell therapies
  • Mechanism of Action Bone marrow cell stimulants; Cell differentiation modulators; Cell replacements; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome; Aplastic anaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Graft-versus-host disease
  • Preclinical Acute radiation syndrome; Chemical burns
  • No development reported Aplastic anaemia

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Aplastic-anaemia in Israel (IM, Injection)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA (IM, Injection)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Graft-versus-host-disease in Israel (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top